Ellsworth Advisors LLC Makes New $516,000 Investment in XOMA Co. (NASDAQ:XOMA)

Ellsworth Advisors LLC acquired a new stake in shares of XOMA Co. (NASDAQ:XOMA) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 19,475 shares of the biotechnology company’s stock, valued at approximately $516,000. Ellsworth Advisors LLC owned approximately 0.17% of XOMA at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares during the period. Rhumbline Advisers lifted its holdings in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of XOMA in the first quarter worth $212,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of XOMA by 55.6% during the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $117.00 price objective on shares of XOMA in a research report on Friday, September 20th.

XOMA Stock Up 1.9 %

Shares of XOMA stock opened at $29.40 on Friday. The firm has a market cap of $343.98 million, a price-to-earnings ratio of -11.81 and a beta of 0.92. The stock has a 50-day simple moving average of $27.75 and a 200-day simple moving average of $26.19. XOMA Co. has a 52-week low of $14.27 and a 52-week high of $30.50. The company has a debt-to-equity ratio of 1.15, a current ratio of 8.71 and a quick ratio of 8.71.

XOMA (NASDAQ:XOMA) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $11.09 million during the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. On average, equities research analysts expect that XOMA Co. will post -1.42 earnings per share for the current fiscal year.

XOMA Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.